Kunihiro Suzuki

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Masanori Shimizu, Kunihiro Suzuki, Kanako Kato et al. · Diabetes Obesity and Metabolism · 2018 · 378 citations

Medicine, Pharmacology, Pharmacotherapy +17

Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function

Kunihiro Suzuki, Gábor Oláh, Katalin Módis et al. · Proceedings of the National Academy of Sciences · 2011 · 283 citations · Full text

Life Sciences, Biochemistry, Physiology +17

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Teruo Jojima, Takanori Tomotsune, Toshie Iijima et al. · Diabetology & Metabolic Syndrome · 2016 · 200 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Co‐administration of proton pump inhibitors delays elimination of plasma methotrexate in high‐dose methotrexate therapy

Kunihiro Suzuki, Kosuke Doki, Masato Homma et al. · British Journal of Clinical Pharmacology · 2008 · 162 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice

Teruo Jojima, Kohsuke Uchida, Kazumi Akimoto et al. · Atherosclerosis · 2017 · 102 citations

Pharmacy, Endocrinology, Pharmacology +17